LENZ Therapeutics Dividenden en inkoop
Dividend criteriumcontroles 0/6
LENZ Therapeutics heeft geen dividenduitkeringen gedaan.
Belangrijke informatie
n/a
Dividendrendement
-87.0%
Terugkoop Rendement
| Totaal aandeelhoudersrendement | -87.0% |
| Toekomstig dividendrendement | 0% |
| Dividendgroei | n/a |
| Volgende betaaldatum dividend | n/a |
| Ex-dividenddatum | n/a |
| Dividend per aandeel | n/a |
| Uitbetalingsratio | n/a |
Recente updates van dividend en inkoop
Recent updates
LENZ Therapeutics: Still Speculative But Priced For Disasters
Summary LENZ Therapeutics is rated a 'Strong Buy' with a fair value estimate of $21.3, reflecting ~266% upside from current levels. I model peak US Vizz sales at $375M, using a 5-pack annualized purchase rate and 30% market share, with conservative international assumptions. LENZ's speculative nature persists due to single-product risk, high SG&A, uninsured status, and rising competition; position sizing remains limited. Short-term signals are mixed, but technicals, insider buying, and potential for a short squeeze reinforce my bullish stance. Read the full article on Seeking Alpha
LENZ: Slower Presbyopia Launch Will Eventually Set Up Future Repricing
The analyst price target for LENZ Therapeutics has shifted from $12 to $7, as analysts point to a slower than expected VIZZ launch, reduced peak sales assumptions, and a focus on cash value, while also acknowledging slightly higher projected profit margins and a lower future P/E in updated models. Analyst Commentary Recent research on LENZ Therapeutics points to a more cautious tone around the VIZZ eye drop launch, with several bearish analysts reducing price targets and reassessing execution risk on the commercial ramp.Earnings Release: Here's Why Analysts Cut Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target To US$26.83
LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) investors will be delighted, with the company turning in some strong numbers...
LENZ: Telehealth Launch And Cash Support Will Shape Future Upside Potential
LENZ Therapeutics now carries a lower analyst price target centered around $7, down from prior expectations closer to $31. Analysts are reassessing the stock in light of slower than expected VIZZ presbyopia launch trends, reduced peak sales assumptions, and a heavier focus on cash value.We're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...LENZ: Telehealth Launch And Advertising Push Will Drive Future Upside Potential
Analysts have reset expectations for LENZ Therapeutics, with the consolidated fair value estimate declining from $53.71 to $32.00 as they factor in updated price targets, a slightly higher discount rate, more moderate revenue growth assumptions, a higher projected profit margin, and a lower future P/E multiple. Analyst Commentary Recent research updates on LENZ Therapeutics point to a more mixed analyst stance, with some focusing on long term upside potential and others emphasizing execution risks and valuation reset drivers.LENZ: Presbyopia Partnership And UK Filing Will Drive Future Repricing
The analyst price target for LENZ Therapeutics has moved from $37.91 to $12.00 as analysts recalibrated their expectations, citing a mix of lower targets from firms like Citi and H.C. Wainwright, a modest upward revision from BofA, and recent rating changes. Analyst Commentary Recent analyst updates for LENZ Therapeutics show a tilt toward more cautious views, with several price targets adjusted and at least one downgrade, which together frame a more conservative stance on the stock.Some LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Just Made A Major Cut To Next Year's Estimates
Today is shaping up negative for LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders, with the analysts delivering a...Earnings Update: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Are Trimming Their Forecasts
It's been a mediocre week for LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders, with the stock dropping 17% to...LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Just Trimmed Their Revenue Forecasts By 12%
Today is shaping up negative for LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders, with the analysts delivering a...Analysts Just Slashed Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) EPS Numbers
Today is shaping up negative for LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders, with the analysts delivering a...LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Are Cutting Their Estimates: Here's What You Need To Know
LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) just released its latest yearly report and things are not looking great. It was...Here's Why We're Not At All Concerned With LENZ Therapeutics' (NASDAQ:LENZ) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Earnings Beat: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) just released its third-quarter report and things are looking bullish. Results...LENZ Therapeutics Stock Is Attractive Before PDUFA
Summary LENZ Therapeutics, Inc.'s LNZ100 eye drop shows promising results for presbyopia, with strong phase 3 data and potential FDA approval by August 2025. LNZ100 demonstrated superior efficacy compared to AbbVie's Vuity, with a broad patient range and rapid onset of treatment effect. Survey data indicates high interest among eye care professionals, with 82% likely to prescribe LNZ100 if approved, targeting a $3bn market. Despite competitive risks, LNZ100's potential market penetration and Lenz's strong financial position make it a cautiously attractive investment. Read the full article on Seeking AlphaCompanies Like LENZ Therapeutics (NASDAQ:LENZ) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...LENZ Therapeutics: Time For A Pause
Summary Today, we take a look Lenz Therapeutics, which may be on the verge of approval for a 'best of breed' solution for near vision loss. The company has a solid balance sheet, is putting a sales organization in place and the compound is very likely to be approved next August. That said, the stock has more than doubled in the past six months and trading levels now exceed most analyst firm price targets. More legs to this rally or are the shares overdue for a pause? An analysis around Lenz Therapeutics follows in the paragraphs below. Read the full article on Seeking AlphaLENZ Therapeutics: Upcoming PDUFA, Strong Data, Some Risks
Summary Graphite Bio reverse merged with Lenz Therapeutics to focus on presbyopia, a $3bn+ market impacting 1.8 billion people globally. LNZ100, a 1.75% Aceclidine eye drop solution, conducted two positive phase 3 clinical trials for presbyopia, showing promising results. LENZ has a market cap of $617mn, cash balance of $226mn, submitted an NDA in August, and has $500mn peak sales estimate. Read the full article on Seeking AlphaStabiliteit en groei van betalingen
Dividenden ophalen
Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van LENZ in het verleden stabiel is geweest.
Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van LENZ zijn gestegen.
Dividendrendement versus markt
| LENZ Therapeutics Dividendrendement versus markt |
|---|
| Segment | Dividendrendement |
|---|---|
| Bedrijf (LENZ) | n/a |
| Markt onderkant 25% (US) | 1.4% |
| Markt Top 25% (US) | 4.1% |
| Gemiddelde industrie (Pharmaceuticals) | 1.9% |
| Analist prognose (LENZ) (tot 3 jaar) | 0% |
Opmerkelijk dividend: Het dividendrendement van LENZ kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Hoog dividend: Het dividendrendement van LENZ kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Winstuitkering aan aandeelhouders
Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio LENZ te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat LENZ geen uitbetalingen heeft gerapporteerd.
Ontdek bedrijven met een sterk dividend
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/14 19:12 |
| Aandelenkoers aan het einde van de dag | 2026/09/14 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
LENZ Therapeutics, Inc. wordt gevolgd door 10 analisten. 7 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Yigal Nochomovitz | Citigroup Inc |
| Matthew Caufield | H.C. Wainwright & Co. |